Use of hyaluronidase for preventing and treating cardio vascular diseases

• US 20050249717A1
• Filed: 05/25/2001
• Published: 11/10/2005
• Est. Priority Date: 05/29/2000
• Status: Abandoned Application

• Current Assignee: Gunther Burgard, Heinz Dieter Cullmann
• Original Assignee: Gunther Burgard, Heinz Dieter Cullmann
• Inventors: Cullmann, Heinz Dieter, Burgard, Gunther
• Application Number:
  US10/296,418
• Publication Number:
  US 20050249717A1
• Time in Patent Office: Days
• US Class Current: 424/94.610
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 38/47 acting on glycosyl compounds (3.2), e.g. cellulases, lactases
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The invention relates to use of the enzyme hyaluronidase in a dosage of at least 6,000 units per day for prevention and/or treatment of cardiovascular diseases whereby the hyaluronidase is administered intra venam over a period of at least four weeks. Hyaluronidase is particularly suited to treating coronary heart diseases as well as for preventive purposes in patients at risk of heart infarctions.

Claims

1-6. -6. (canceled)

7. A method of preventing and/or treating cardiovascular disease, which method comprises intravenously administering to a patient at least 6,000 units per day of hyaluronidase for at least four weeks, whereupon cardiovascular disease in the patient is treated and/or prevented.

8. The method of claim 7, which method comprises intravenously administering to the patient at least 12,000 units per day of hyaluronidase.

9. The method of claim 8, which method comprises intravenously administering to the patient at least 15,000 units per day of hyaluronidase.

10. The method of claim 7, which method further comprises administering one or more agents selected from the group consisting of carnitin, a cholesterol synthesizing enzyme (CSE) inhibitor, a nootropic, a blood supply enhancer, a vitamin, and a cation.

11. The method of claim 8, which method further comprises administering one or more agents selected from the group consisting of carnitin, a CSE inhibitor, a nootropic, a blood supply enhancer, a vitamin, and a cation.

12. The method of claim 9, which method further comprises administering one or more agents selected from the group consisting of carnitin, a CSE inhibitor, a nootropic, a blood supply enhancer, a vitamin, and a cation.

13. The method of claim 7, which method comprises administering hyaluronidase for at least two months.

14. The method of claim 8, which method comprises administering hyaluronidase for at least two months.

15. The method of claim 9, which method comprises administering hyaluronidase for at least two months.

16. The method of claim 10, which method comprises administering hyaluronidase and one or more other agents for at least two months.

17. The method of claim 11, which method comprises administering hyaluronidase and one or more other agents for at least two months.

18. The method of claim 12, which method comprises administering hyaluornidase and one or more other agents for at least two months.

19. The method of claim 7, wherein the cardiovascular disease involves coronary heart disease, arteriosclerosis, carotid stenosis, stenosis of arteries leading to the brain, cardiac infarction, apoplexy, cardiac hypertrophy, or fatty disease of the heart.

20. The method of claim 8, wherein the cardiovascular disease involves coronary heart disease, arteriosclerosis, carotid stenosis, stenosis of arteries leading to the brain, cardiac infarction, apoplexy, cardiac hypertrophy, or fatty disease of the heart.

21. The method of claim 9, wherein the cardiovascular disease involves coronary heart disease, arteriosclerosis, carotid stenosis, stenosis of arteries leading to the brain, cardiac infarction, apoplexy, cardiac hypertrophy, or fatty disease of the heart.

22. The method of claim 10, wherein the cardiovascular disease involves coronary heart disease, arteriosclerosis, carotid stenosis, stenosis of arteries leading to the brain, cardiac infarction, apoplexy, cardiac hypertrophy, or fatty disease of the heart.

23. The method of claim 11, wherein the cardiovascular disease involves coronary heart disease, arteriosclerosis, carotid stenosis, stenosis of arteries leading to the brain, cardiac infarction, apoplexy, cardiac hypertrophy, or fatty disease of the heart.

24. The method of claim 12, wherein the cardiovascular disease involves coronary heart disease, arteriosclerosis, carotid stenosis, stenosis of arteries leading to the brain, cardiac infarction, apoplexy, cardiac hypertrophy, or fatty disease of the heart.

25. The method of claim 13, wherein the cardiovascular disease involves coronary heart disease, arteriosclerosis, carotid stenosis, stenosis of arteries leading to the brain, cardiac infarction, apoplexy, cardiac hypertrophy, or fatty disease of the heart.

26. The method of claim 14, wherein the cardiovascular disease involves coronary heart disease, arteriosclerosis, carotid stenosis, stenosis of arteries leading to the brain, cardiac infarction, apoplexy, cardiac hypertrophy, or fatty disease of the heart.

27. The method of claim 15, wherein the cardiovascular disease involves coronary heart disease, arteriosclerosis, carotid stenosis, stenosis of arteries leading to the brain, cardiac infarction, apoplexy, cardiac hypertrophy, or fatty disease of the heart.

28. The method of claim 16, wherein the cardiovascular disease involves coronary heart disease, arteriosclerosis, carotid stenosis, stenosis of arteries leading to the brain, cardiac infarction, apoplexy, cardiac hypertrophy, or fatty disease of the heart.

29. The method of claim 17, wherein the cardiovascular disease involves coronary heart disease, arteriosclerosis, carotid stenosis, stenosis of arteries leading to the brain, cardiac infarction, apoplexy, cardiac hypertrophy, or fatty disease of the heart.

30. The method of claim 18, wherein the cardiovascular disease involves coronary heart disease, arteriosclerosis, carotid stenosis, stenosis of arteries leading to the brain, cardiac infarction, apoplexy, cardiac hypertrophy, or fatty disease of the heart.

31. A method of preventing and/or treating cardiovascular disease, which method comprises administering to a patient at least 6,000 units per day of hyaluronidase for at least four weeks whereupon cardiovascular disease in the patient is treated and/or prevented.